1. Elevated Admission Plasma Glucose Following ACS

2. Background

3. Trial Design

4. MACE After 180 Days Based on Admission Glucose Levels

5. Conclusions

6. Long-Term Secondary Prevention With Ticagrelor

7. Background

8. Primary Endpoint by History of Coronary Stent Composite of CV Death, MI, or Stroke

9. Safety Endpoints Bleeding According to Prior Stenting

10. All-Cause Mortality

11. Conclusions

12. Patient Selection for Long-Term Secondary Prevention With Ticagrelor

13. PEGASUS-TIMI 54 Ticagrelor in Patients With Prior MI

14. Optimizing Treatment Through Patient Selection

15. Derivation of Risk Score

16. Patient Selection Algorithm

17. Summary

18. Potential Impact of the Latest Data in Clinical Practice

19. 3 Key Studies in Patients With ACS

20. Summary and Clinical Implications

21. Abbreviations